Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiora Pharmaceuticals (KPRX) Equity Ratio (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Equity Ratio for 11 consecutive years, with 0.75 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Equity Ratio fell 3.77% year-over-year to 0.75, compared with a TTM value of 0.75 through Sep 2025, down 3.77%, and an annual FY2024 reading of 0.71, up 58.46% over the prior year.
  • Equity Ratio was 0.75 for Q3 2025 at Kiora Pharmaceuticals, up from 0.69 in the prior quarter.
  • Across five years, Equity Ratio topped out at 118.33 in Q3 2021 and bottomed at 0.45 in Q4 2023.
  • Average Equity Ratio over 5 years is 7.6, with a median of 0.71 recorded in 2024.
  • The sharpest move saw Equity Ratio soared 18251.37% in 2021, then tumbled 99.5% in 2022.
  • Year by year, Equity Ratio stood at 0.72 in 2021, then fell by 17.75% to 0.6 in 2022, then dropped by 25.2% to 0.45 in 2023, then skyrocketed by 58.46% to 0.71 in 2024, then rose by 6.29% to 0.75 in 2025.
  • Business Quant data shows Equity Ratio for KPRX at 0.75 in Q3 2025, 0.69 in Q2 2025, and 0.71 in Q4 2024.